{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:53:32Z","timestamp":1772556812807,"version":"3.50.1"},"reference-count":16,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Optimal valganciclovir dosing for cytomegalovirus (CMV) prophylaxis in pediatric solid organ transplant recipients remains difficult due to variable pharmacokinetics. This study compared the efficacy and safety of three dosing strategies: body surface area (BSA)-based, weight-based, and Pescovitz algorithm-based dosing. This retrospective cohort study included pediatric patients aged \u226414 years who underwent kidney or liver transplantation between 2010 and 2018 and received valganciclovir for CMV prophylaxis. The primary outcome was the comparative effectiveness of the three dosing approaches in preventing CMV infection and disease. The study included 150 patients, with 50 in each group. CMV infection occurred more frequently in the BSA-based group than in the Pescovitz algorithm-based or weight-based groups. Among patients who developed CMV DNAemia, CMV disease occurred in 54%, 28%, and 50% of patients in the BSA-based, Pescovitz algorithm-based, and weight-based groups, respectively. No tissue-invasive CMV disease was observed within 12 months after transplantation. All groups showed acceptable safety profiles, and no patients discontinued therapy due to hematologic adverse events. Weight-based dosing was associated with lower CMV infection and disease rates than BSA-based dosing and Pescovitz algorithm-based dosing, with similar safety. In pediatric solid organ transplant recipients, valganciclovir dosing strategy was not independently associated with CMV infection after adjustment. Age emerged as the sole independent predictor of CMV risk, underscoring the predominance of patient-related factors in CMV prophylaxis.<\/jats:p>","DOI":"10.3390\/v18030297","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:55:01Z","timestamp":1772463301000},"page":"297","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Valganciclovir Dosing Strategies for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients: A Comparative Single-Center Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2249-3713","authenticated-orcid":false,"given":"Samar","family":"Alharbi","sequence":"first","affiliation":[{"name":"Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delal","family":"Alkortas","sequence":"additional","affiliation":[{"name":"College of Medicine, Al-Faisal University, Riyadh 11533, Saudi Arabia"},{"name":"College of Pharmacy, Al-Faisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-8853","authenticated-orcid":false,"given":"Dema","family":"Alissa","sequence":"additional","affiliation":[{"name":"College of Medicine, Al-Faisal University, Riyadh 11533, Saudi Arabia"},{"name":"College of Pharmacy, Al-Faisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-9928","authenticated-orcid":false,"given":"Aziza","family":"Ajlan","sequence":"additional","affiliation":[{"name":"Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinah","family":"Alabdulkarim","sequence":"additional","affiliation":[{"name":"College of Medicine, Al-Faisal University, Riyadh 11533, Saudi Arabia"},{"name":"College of Pharmacy, Al-Faisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-0683","authenticated-orcid":false,"given":"Hala","family":"Joharji","sequence":"additional","affiliation":[{"name":"College of Medicine, Al-Faisal University, Riyadh 11533, Saudi Arabia"},{"name":"College of Pharmacy, Al-Faisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4291-8536","authenticated-orcid":false,"given":"Khalid","family":"Alhasan","sequence":"additional","affiliation":[{"name":"Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"},{"name":"College of Medicine, King Saud University, Riyadh 11362, Saudi Arabia"},{"name":"Pediatric Department, King Saud University Medical City, Riyadh 11362, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward Bentz","family":"Devol","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology & Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0251-1894","authenticated-orcid":false,"given":"Dalia","family":"Obeid","sequence":"additional","affiliation":[{"name":"Transplant Research and Innovation Department, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Al-jedai","sequence":"additional","affiliation":[{"name":"College of Medicine, Al-Faisal University, Riyadh 11533, Saudi Arabia"},{"name":"College of Pharmacy, Al-Faisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jpids\/pir001","article-title":"Infections in pediatric solid organ transplant recipients","volume":"1","author":"Green","year":"2012","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.3748\/wjg.v20.i31.10658","article-title":"Cytomegalovirus infection in liver transplant recipients: Updates on clinical management","volume":"20","author":"Marcelin","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/INF.0000000000001595","article-title":"Valganciclovir dosing for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients","volume":"36","author":"Peled","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00003088-200948050-00004","article-title":"Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients","volume":"48","author":"Zhao","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1399-3046.2006.00669.x","article-title":"Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children","volume":"11","author":"Vethamuthu","year":"2007","journal-title":"Pediatr. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1399-3062.2009.00478.x","article-title":"Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients","volume":"12","author":"Pescovitz","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1600-6143.2008.02528.x","article-title":"Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients","volume":"9","author":"Vaudry","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/petr.12179","article-title":"New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients","volume":"18","author":"Bjerre","year":"2014","journal-title":"Pediatr. Transplant."},{"key":"ref_11","unstructured":"(2016, December 25). Valcyte\u00ae Label Information, Available online: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021304s008,022257s003lbl.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/petr.12030","article-title":"Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients","volume":"17","author":"Villeneuve","year":"2012","journal-title":"Pediatr. Transplant."},{"key":"ref_13","unstructured":"(2010, September 15). FDA Drug Safety Communication, Available online: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm225727.htm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ajt.2023.07.013","article-title":"Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients","volume":"23","author":"Demirhan","year":"2023","journal-title":"Am. J. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014Guidelines of the American society of transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin. Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/3\/297\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:48:15Z","timestamp":1772549295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/3\/297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["v18030297"],"URL":"https:\/\/doi.org\/10.3390\/v18030297","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}